The U.S. Food and Drug Administration (FDA) has approved the Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease after months of delays. Clinical trials of the new drug were performed on 1736 patients with mild cognitive impairment or mild dementia and ...
More »